Opportunities and challenges of using five‐membered ring compounds as promising antitubercular agents

Abstract Tuberculosis (TB), a chronic infectious disease, is one of the greatest risks to human beings and 10 million people were diagnosed with TB and 1.6 million died from this disease in 2017. In addition, with the emergence of multidrug‐resistant tuberculosis (MDR‐TB) and extensively drug‐resistant tuberculosis (XDR‐TB), the TB situation has become even worse, which has aggravated the mortality and spread of this disease. To overcome this problem, research into novel antituberculosis agents with enhanced activities against MDR‐TB, reduced toxicity, and shortened duration of therapy is of great importance. Fortunately, many novel potential anti‐TB drug candidates with five‐membered rings, which are most likely to be effective against sensitive and resistant strains, have recently entered clinical trials. Different five‐membered rings such as furans, pyranoses, thiazoles, pyrazolines, imidazoles, oxazolidinone, thiazolidins, isoxazoles, triazoles, oxadiazoles, thiadiazoles, and tetrazoles have been designed, prepared, and evaluated for their antimycobacterial activity against M ycobacterium tuberculosis . In this article, we highlight the recent advances made in the discovery of novel five‐membered ring compounds and focus on their antitubercular activities, toxicity, structure–activity relationships, and mechanisms of action.